Intercept 'on track' to re-submit NDA

 U.S. Ocaliva® net sales of $77.6 million; 16.4% growth over the prior year quarter

Company increases 2022 Ocaliva non-GAAP adjusted net sales guidance to $340 million to $350 million and narrows non-GAAP adjusted operating expense guidance to $350 million to $365 million

As of September 30, 2022, Company has cash, cash equivalents, restricted cash, and investment debt securities available for sale of $497.8 million

Company remains on track to resubmit new drug application (NDA) for obeticholic acid (OCA) in liver fibrosis due to NASH by end of 2022 based on the positive Phase 3 REGENERATE study

https://finance.yahoo.com/news/intercept-pharmaceuticals-reports-third-quarter-110000449.html